Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Amolyt Pharma SAS

Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. *


Period Start 2020-06-02 renamed
  Group AstraZeneca (Group)
  Predecessor Alizé Pharma III SAS (Alizé Pharma 3)
Product Industry peptide-based drug
Person Person Abribat, Thierry (Alizé Pharma 2007– President + Founder)
Region Region Lyon
  Country France
  Street 15 chemin du Saquin
Espace Européen
  City 69130 Ecully
    Address record changed: 2024-01-05
Basic data Employees n. a.
    * Document for »About Section«: Amolyt Pharma SAS. (3/14/24). "Press Release: Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca. AstraZeneca Will Acquire Amolyt Pharma for up to $1.05 Billion in Total Consideration". Lyon & Cambridge, MA.
Record changed: 2024-05-16


Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group World of Partnering Opportunities 650x300px

» top